References
- Anwar-Mohamed A, Barakat KH, Bhat R, et al. A human ether-á-go-go-related (hERG) ion channel atomistic model generated by long supercomputer molecular dynamics simulations and its use in predicting drug cardiotoxicity. Toxicol Lett. 2014;230(3):382–392.
- Kalyaanamoorthy S, Barakat KH. Development of safe drugs: the hERG challenge. Med Res Rev. Forthcoming 2017. DOI:10.1002/med.21445.
- Boyer S, Brealey C, Davis AM. Attrition in drug discovery and development. Attrition in the pharmaceutical industry. John Wiley & Sons, Inc, Hoboken, NJ. 2015. 5–45.
- Villoutreix BO, Taboureau O. Computational investigations of hERG channel blockers: new insights and current predictive models. Adv Drug Deliv Rev. 2015;86:72–82.
- Vandenberg JI, Perozo E, Allen TW. Towards a structural view of drug binding to hERG K+ channels. Trends Pharmacol Sci. 2017;38(10):899–907.
- Colatsky T, Fermini B, Gintant G, et al. The Comprehensive in vitro proarrhythmia assay (CiPA) initiative — update on progress. J Pharmacol Toxicol Methods. 2016;81:15–20.
- Laverty HG, Benson C, Cartwright EJ, et al. How can we improve our understanding of cardiovascular safety liabilities to develop safer medicines? Br J Pharmacol. 2011;163(4):675–693.
- Kreusch A, Pfaffinger PJ, Stevens CF, et al. Crystal structure of the tetramerization domain of the Shaker potassium channel. Nature. 1998;392(6679):945–948.
- Jiang Y, Lee A, Chen J, et al. X-ray structure of a voltage-dependent K+ channel. Nature. 2003;423(6935):33–41.
- Lenaeus MJ, Vamvouka M, Focia PJ, et al. Structural basis of TEA blockade in a model potassium channel. Nat Struct Mol Biol. 2005;12(5):454–459.
- Whicher JR, MacKinnon R. Structure of the voltage-gated K+ channel Eag1 reveals an alternative voltage sensing mechanism. Science. 2016;353(6300):664.
- Long SB, Campbell EB, MacKinnon R. Crystal structure of a mammalian voltage-dependent shaker family K+ channel. Science. 2005;309(5736):897–903.
- Bowes J, Brown AJ, Hamon J, et al. Reducing safety-related drug attrition: the use of in vitro pharmacological profiling. Nat Rev Drug Discov. 2012;11:909.
- Durdagi S, Subbotina J, Lees-Miller J, et al. Insights into the molecular mechanism of hERG1 channel activation and blockade by drugs. Curr Med Chem. 2010;17(30):3514–3532.
- Mitcheson JS, Chen J, Sanguinetti MC. Trapping of a methanesulfonanilide by closure of the hERG potassium channel activation gate [10.1085/jgp.115.3.229]. The Journal of General Physiology. 2000;115(3):229.
- Saxena P, Zangerl-Plessl EM, Linder T, et al. New potential binding determinant for hERG channel inhibitors. Sci Rep. 2016;6:24182.
- Wang W, MacKinnon R. Cryo-EM structure of the open human Ether-à-go-go-related K+ channel hERG. Cell. 2017;169(3):422–430.e10.
- Vandenberg JI, Perry MD, Perrin MJ, et al. hERG K+ channels: structure, function, and clinical significance. Physiol Rev. 2012;92(3):1393.
- Aronov AM. Predictive in silico modeling for hERG channel blockers. Drug Discov Today. 2005;10(2):149–155.
- Perry M, Stansfeld PJ, Leaney J, et al. Drug binding interactions in the inner cavity of hERG channels: molecular insights from structure-activity relationships of clofilium and ibutilide analogs. Mol Pharmacol. 2006;69(2):509–519.
- Ridley JM, Milnes JT, Witchel HJ, et al. High affinity HERG K+ channel blockade by the antiarrhythmic agent dronedarone: resistance to mutations of the S6 residues Y652 and F656. Biochem Biophys Res Commun. 2004;325(3):883–891.
- Wang Y, Guo J, Perissinotti LL, et al. Role of the pH in state-dependent blockade of hERG currents. Sci Rep. 2016;6:32536.
- Perrin MJ, Kuchel PW, Campbell TJ, et al. Drug binding to the inactivated state is necessary but not sufficient for high-affinity binding to human Ether-à-go-go-related gene channels. Mol Pharmacol. 2008;74(5):1443.
- Gintant G, Sager PT, Stockbridge N. Evolution of strategies to improve preclinical cardiac safety testing. Nat Rev Drug Discov. 2016;15(7):457–471.
- De Ponti F. Pharmacological and regulatory aspects of QT prolongation. Antitargets. Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim, Germany; 2008. p. 53–88.
- Gedeck P, Kramer C, Lewis R. In silico approaches to address compound attrition. Attrition in the Pharmaceutical Industry. John Wiley & Sons, Inc, Hoboken, NJ; 2015. p. 264–286.